Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Cellular and Molecular Biology Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran.
J Biochem Mol Toxicol. 2021 Apr;35(4):e22688. doi: 10.1002/jbt.22688. Epub 2020 Dec 28.
A series of new benzofuran-1,3,4-oxadiazole containing 1,2,3-triazole-acetamides 12a-n as potential anti-α-glucosidase agents were designed and synthesized. α-Glucosidase inhibition assay demonstrated that all the synthesized compounds 12a-n (half-maximal inhibitory concentration [IC ] values in the range of 40.7 ± 0.3-173.6 ± 1.9 μM) were more potent than standard inhibitor acarbose (IC = 750.0 ± 12.5 µM). Among them, the most potent compound was compound 12c, with inhibitory activity around 19-fold higher than acarbose. Since the most potent compound inhibited α-glucosidase in a competitive mode, a docking study of this compound was also performed into the active site of α-glucosidase. In vitro and in silico toxicity assays of the title compounds were also performed.
一系列含有 1,2,3-三唑乙酰胺的新型苯并呋喃-1,3,4-噁二唑 12a-n 被设计并合成,作为潜在的抗α-葡萄糖苷酶试剂。α-葡萄糖苷酶抑制试验表明,所有合成的化合物 12a-n(半数最大抑制浓度 [IC ] 值在 40.7 ± 0.3-173.6 ± 1.9 μM 范围内)均比标准抑制剂阿卡波糖(IC = 750.0 ± 12.5 μM)更有效。其中,活性最强的化合物是 12c,其抑制活性约比阿卡波糖高 19 倍。由于最有效的化合物以竞争模式抑制α-葡萄糖苷酶,因此还对该化合物在α-葡萄糖苷酶活性部位进行了对接研究。还对标题化合物进行了体外和计算毒性试验。